Coagulation factor xiv or protein c

Immunogen coiled-coil domain containing 56 recombinant protein epitope signature tag (PrEST) Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are

Immunogen cytochrome c oxidase assembly factor 5 Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive

Anti-Factor VII antibody, mouse monoclonal (mouse) IgG1 isotype) is derived from the HVII-1 hybridoma produced by the fusion of mouse Sp2/0-Ag14 myeloma cells and splenocytes from immunized BAB/c mice. Human coagulation factor VII contains 10

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the

C-reactive protein (CRP), a homopentameric acute-phase inflammatory protein, is produced mainly in liver hepatocytes. This highly conserved plasma protein is also produced by smooth muscle cells, macrophages, endothelial cells, lymphocytes, and

C-reactive protein (CRP) is a homopentameric acute-phase inflammatory protein, which belongs to the pentraxin family. It is a highly conserved plasma protein produced mainly in liver hepatocytes.

M.W.

Native coagulation factor &#945-XIIa from human plasma prepared from homogeneous Factor XII using dextran sulfate. Dextran sulfate is removed after activation.

Native, human, activated, C1r complement component. Generally the non-activated form composed of a single-chain glycoprotein.

Crovalimab (anti-Complement C5) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab (anti-Complement C5) binds human FcRn with great affinity (KD: 17 μM at pH

Crovalimab (anti-Complement C5) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab (anti-Complement C5) binds human FcRn with great affinity (KD: 17 μM at pH

Crovalimab (anti-Complement C5) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab (anti-Complement C5) binds human FcRn with great affinity (KD: 17 μM at pH